Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
- FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
- Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
December 25, 2015
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
- JPMA Reprimands Novartis over Side Effect Reporting Violation
December 18, 2015
- JPMA to Watch Regulators’ Moves to Decide Its Action on Kaketsuken
December 18, 2015
- JPMA Says Re-Pricing of Huge-Seller Drugs Unreasonable, Preparing Statement
December 18, 2015
- Lilly’s Jonsson to Become Japan Chief of PhRMA
December 18, 2015
- PhRMA Sounds Alarm on “Huge Seller” Re-Pricing, Possible Decline in Japan Investment
December 14, 2015
- JGA Chief Opposes 50% First Generic Pricing for Non-Oral Drugs with Adoair, Symbicort Generics in Mind
December 11, 2015
- JPMA Sets to Respond Harshly to Kaketsuken Cover-Up: Chief
December 8, 2015
- JPMA Requests on Price Revisions, Tax Seem to Have Sunk in for Politicians: Exec
November 20, 2015
- 6 Insurers Tender Request for FY2016 Reform, Say Healthcare Costs Must Be Cut with HTA, Generics
November 19, 2015
- Industry Wants OTC Tax Break and No Annual Price Cuts, Groups Tell LDP
November 19, 2015
- Pharma Leaders Rev Up Lobbying Campaigns ahead of Year-End Budget, Tax Debates
November 18, 2015
- FPMAJ Gives Up on Crafting Rules for Disclosing Joint Generic Developers
October 27, 2015
- Reflect Industry Opinions in Pilot Introduction of Cost-Effective Assessments: JPMA
October 27, 2015
- JPMA Says Its Demands Generally Accepted in TPP, No Impact Expected on Japan Market
October 23, 2015
- EFPIA Poised to Lobby Japan on Vaccine Regulations in EPA Talks
October 22, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…